Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology - PubMed (original) (raw)
Practice Guideline
. 2021 Mar 2;19(3):329-359.
doi: 10.6004/jnccn.2021.0012.
Alan P Venook 2, Mahmoud M Al-Hawary 3, Mustafa A Arain 2, Yi-Jen Chen 4, Kristen K Ciombor 5, Stacey Cohen 6, Harry S Cooper 7, Dustin Deming 8, Linda Farkas 9, Ignacio Garrido-Laguna 10, Jean L Grem 11, Andrew Gunn 12, J Randolph Hecht 13, Sarah Hoffe 14, Joleen Hubbard 15, Steven Hunt 16, Kimberly L Johung 17, Natalie Kirilcuk 18, Smitha Krishnamurthi 19, Wells A Messersmith 20, Jeffrey Meyerhardt 21, Eric D Miller 22, Mary F Mulcahy 1, Steven Nurkin 23, Michael J Overman 24, Aparna Parikh 25, Hitendra Patel 26, Katrina Pedersen 16, Leonard Saltz 27, Charles Schneider 28, David Shibata 29, John M Skibber 24, Constantinos T Sofocleous 27, Elena M Stoffel 3, Eden Stotsky-Himelfarb 30, Christopher G Willett 31, Kristina M Gregory 32, Lisa A Gurski 32
Affiliations
- PMID: 33724754
- DOI: 10.6004/jnccn.2021.0012
Practice Guideline
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Al B Benson et al. J Natl Compr Canc Netw. 2021.
Abstract
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer focuses on systemic therapy options for the treatment of metastatic colorectal cancer (mCRC), because important updates have recently been made to this section. These updates include recommendations for first-line use of checkpoint inhibitors for mCRC, that is deficient mismatch repair/microsatellite instability-high, recommendations related to the use of biosimilars, and expanded recommendations for biomarker testing. The systemic therapy recommendations now include targeted therapy options for patients with mCRC that is HER2-amplified, or BRAF V600E mutation-positive. Treatment and management of nonmetastatic or resectable/ablatable metastatic disease are discussed in the complete version of the NCCN Guidelines for Colon Cancer available at NCCN.org. Additional topics covered in the complete version include risk assessment, staging, pathology, posttreatment surveillance, and survivorship.
Similar articles
- Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Gunn A, Hecht JR, Hoffe S, Hubbard J, Hunt S, Jeck W, Johung KL, Kirilcuk N, Krishnamurthi S, Maratt JK, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stotsky-Himelfarb E, Tavakkoli A, Willett CG, Gregory K, Gurski L. Benson AB, et al. J Natl Compr Canc Netw. 2022 Oct;20(10):1139-1167. doi: 10.6004/jnccn.2022.0051. J Natl Compr Canc Netw. 2022. PMID: 36240850 - NCCN Guidelines Insights: Colon Cancer, Version 2.2018.
Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Garrido-Laguna I, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Freedman-Cass DA. Benson AB, et al. J Natl Compr Canc Netw. 2018 Apr;16(4):359-369. doi: 10.6004/jnccn.2018.0021. J Natl Compr Canc Netw. 2018. PMID: 29632055 Free PMC article. - NCCN Guidelines Insights: Rectal Cancer, Version 6.2020.
Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Gunn A, Hoffe S, Hubbard J, Hunt S, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Johnson-Chilla A, Gurski LA. Benson AB, et al. J Natl Compr Canc Netw. 2020 Jul;18(7):806-815. doi: 10.6004/jnccn.2020.0032. J Natl Compr Canc Netw. 2020. PMID: 32634771 - Targeting Colon Cancers with Mutated BRAF and Microsatellite Instability.
Matos P, Jordan P. Matos P, et al. Adv Exp Med Biol. 2018;1110:7-21. doi: 10.1007/978-3-030-02771-1_2. Adv Exp Med Biol. 2018. PMID: 30623363 Review. - Clinical Updates for Colon Cancer Care in 2022.
Fabregas JC, Ramnaraign B, George TJ. Fabregas JC, et al. Clin Colorectal Cancer. 2022 Sep;21(3):198-203. doi: 10.1016/j.clcc.2022.05.006. Epub 2022 Jun 3. Clin Colorectal Cancer. 2022. PMID: 35729033 Review.
Cited by
- Impact of Glutamine-Enhanced Parenteral Nutrition on Postoperative Outcomes in Colorectal Cancer Patients.
Huang Y, Yin C, Wang J, Wang M, Zheng X, Xie M, Wang J. Huang Y, et al. Cancer Manag Res. 2024 Oct 2;16:1329-1344. doi: 10.2147/CMAR.S476648. eCollection 2024. Cancer Manag Res. 2024. PMID: 39372706 Free PMC article. - Poor compliance with germline testing recommendations in colorectal cancer patients undergoing molecular residual disease testing.
Schrock-Kelley S, Souter V, Hall MJ, Sha Y, Sengupta U, ElNaggar AC, Liu MC, Weitzel JN. Schrock-Kelley S, et al. Commun Med (Lond). 2024 Sep 30;4(1):185. doi: 10.1038/s43856-024-00608-6. Commun Med (Lond). 2024. PMID: 39349798 Free PMC article. - Exploring prognostic biomarkers in pathological images of colorectal cancer patients via deep learning.
Wei B, Li L, Feng Y, Liu S, Fu P, Tian L. Wei B, et al. J Pathol Clin Res. 2024 Nov;10(6):e70003. doi: 10.1002/2056-4538.70003. J Pathol Clin Res. 2024. PMID: 39343999 Free PMC article. - Cancer-Associated Fibroblast Proteins as Potential Targets against Colorectal Cancers.
Shah R, Johnson KA, Lippert AEL, Kraus SG, Emmerich PB, Pasch CA, Zhang W, Matkowskyj KA, LeBeau AM, Deming DA. Shah R, et al. Cancers (Basel). 2024 Sep 14;16(18):3158. doi: 10.3390/cancers16183158. Cancers (Basel). 2024. PMID: 39335130 Free PMC article. - Clinician perceptions on barriers and facilitators to 1-year surveillance colonoscopy completion in survivors of colorectal cancer.
Kwendakwema CN, Hopkins T, Bell-Brown A, Simianu VV, Shankaran V, Issaka RB. Kwendakwema CN, et al. Cancer Med. 2024 Sep;13(18):e70244. doi: 10.1002/cam4.70244. Cancer Med. 2024. PMID: 39315598 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous